New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
09:28 EDTMNKD MannKind volatility expected to move on FDA approval of Afrezza
MannKind volatility is expected to move after company confirms FDA approval of Afrezza inhalation powder to improve glycemic control in adult patients with diabetes. Overall option implied volatility of 80 is below its 26-week average of 102 according to Track Data, suggesting decreasing price movement.
News For MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
09:56 EDTMNKDOptions with increasing volume on open
Subscribe for More Information
09:03 EDTMNKDMannKind triples production capacity for Afrezza
MannKind announced that it has completed the validation of two additional filling lines for the manufacture of Afrezza inhalation powder. Material produced during the validation runs, including the recently approved 12 unit cartridges, will be supplied to Sanofi to support the launch of the new dosage strength, which is expected later this quarter.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use